Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free DNTH Stock Alerts

Dianthus Therapeutics (DNTH) Financials

Dianthus Therapeutics logo
$101.28 +2.64 (+2.68%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$101.14 -0.14 (-0.14%)
As of 07:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Dianthus Therapeutics

Annual Income Statements for Dianthus Therapeutics

This table shows Dianthus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.74 -36 -58 -77 -75 -71 -28 -44 -85 -162
Consolidated Net Income / (Loss)		 -9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Net Income / (Loss) Continuing Operations		 -9.43 -35 -58 -77 -75 -71 -28 -44 -85 -163
Total Pre-Tax Income 		-9.43 -35 -58 -77 -75 -71 -28 -44 -85 -163
Total Operating Income		 -9.27 -36 -60 -83 -79 -75 -30 -48 -102 -178
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 6.42 2.83 6.24 2.04
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 6.42 2.83 6.24 2.04
Operating Revenue		 0.00 0.00 0.00 - - - 6.42 2.83 6.24 2.04
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.27 36 60 83 79 75 36 51 108 180
Selling, General & Admin Expense		 3.49 7.83 19 24 28 28 6.74 18 25 34
Research & Development Expense		 5.78 28 41 59 51 47 29 33 83 146
Total Other Income / (Expense), net		 -0.16 0.24 2.45 6.20 3.77 3.56 1.23 4.62 17 16
Interest & Investment Income		 0.00 0.24 2.45 6.20 3.77 3.56 1.15 4.76 17 16
Other Income / (Expense), net		 - - - - - - 0.08 -0.15 -0.62 -1.03
Basic Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($32.57) ($8.45) ($2.55) ($4.20)
Weighted Average Basic Shares Outstanding		 149.41K 1.86M 18.39M 37.01M 43.92M 54.95M 874.23K 5.15M 33.31M 38.62M
Diluted Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($32.57) ($8.45) ($2.55) ($4.20)
Weighted Average Diluted Shares Outstanding		 149.41K 1.86M 18.39M 37.01M 43.92M 54.95M 874.23K 5.15M 33.31M 38.62M
Weighted Average Basic & Diluted Shares Outstanding		 149.41K 1.86M 18.39M 37.01M 43.92M 58.80M 60.64M 29.35M 32.13M 44.47M
Cash Dividends to Common per Share		 - - - - - - - $0.00 $0.00 $0.00

Quarterly Income Statements for Dianthus Therapeutics

This table shows Dianthus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -64 -41
Consolidated Net Income / (Loss)		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -64 -41
Net Income / (Loss) Continuing Operations		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -65 -41
Total Pre-Tax Income 		-15 -11 -14 -18 -25 -28 -30 -32 -37 -65 -41
Total Operating Income		 -16 -13 -18 -22 -30 -32 -33 -35 -40 -70 -47
Total Gross Profit		 0.92 0.46 0.87 1.86 2.17 1.33 1.16 0.00 0.00 0.87 0.00
Total Revenue		 0.92 0.46 0.87 1.86 2.17 1.33 1.16 0.00 0.00 0.87 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 17 13 19 24 32 33 34 35 41 70 47
Selling, General & Admin Expense		 8.72 4.63 5.64 6.00 6.53 6.83 7.34 8.87 8.20 9.93 12
Research & Development Expense		 7.96 8.78 13 18 26 26 27 26 32 60 35
Total Other Income / (Expense), net		 1.00 2.39 4.10 4.60 4.73 3.48 3.67 3.30 3.52 5.11 5.70
Interest & Investment Income		 1.03 2.44 4.22 4.71 4.45 3.99 3.79 3.40 3.66 5.27 6.27
Other Income / (Expense), net		 -0.03 -0.05 -0.13 -0.11 0.28 -0.51 -0.13 -0.14 -0.36 -0.41 -0.26
Basic Earnings per Share		 ($3.78) $16.16 ($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85)
Weighted Average Basic Shares Outstanding		 3.91M 5.15M 25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M
Diluted Earnings per Share		 ($3.78) $16.16 ($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85)
Weighted Average Diluted Shares Outstanding		 3.91M 5.15M 25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M
Weighted Average Basic & Diluted Shares Outstanding		 14.82M 29.35M 29.35M 29.35M 29.60M 32.13M 32.16M 32.19M 42.88M 44.47M 54.67M
Cash Dividends to Common per Share		 - - $0.00 - - - $0.00 - - - $0.00

Annual Cash Flow Statements for Dianthus Therapeutics

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.04 47 8.56 6.73 -6.92 73 7.79 117 -109 28
Net Cash From Operating Activities		 -6.53 -22 -42 -57 -64 -60 -29 -37 -78 -129
Net Cash From Continuing Operating Activities		 -6.53 -22 -42 -57 -64 -60 -29 -37 -78 -129
Net Income / (Loss) Continuing Operations		 -9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Consolidated Net Income / (Loss)		 -9.43 -35 -58 -77 -75 -71 -28 -44 -85 -162
Depreciation Expense		 0.01 0.38 0.88 1.84 1.98 2.02 0.03 0.07 0.10 0.11
Amortization Expense		 0.00 0.00 -0.19 -1.01 0.18 - -0.49 -1.14 -5.70 -5.85
Non-Cash Adjustments To Reconcile Net Income		 1.30 12 11 10 9.94 10 1.59 3.65 12 22
Changes in Operating Assets and Liabilities, net		 1.60 1.32 4.17 8.83 -1.19 -1.53 -1.72 4.11 -0.02 17
Net Cash From Investing Activities		 -0.14 -2.20 -92 1.53 -11 43 -60 20 -287 -123
Net Cash From Continuing Investing Activities		 -0.14 -2.20 -92 1.53 -11 43 -60 20 -287 -123
Purchase of Property, Plant & Equipment		 -0.14 -2.20 -7.67 -3.06 -0.40 -1.26 -0.14 -0.11 -0.11 -0.21
Purchase of Investments		 0.00 0.00 -84 -144 -96 -45 -62 -57 -414 -435
Sale and/or Maturity of Investments		 - 0.00 0.00 149 86 90 2.00 78 127 312
Net Cash From Financing Activities		 11 71 142 62 68 90 97 134 256 280
Net Cash From Continuing Financing Activities		 11 71 142 62 68 90 97 134 256 280
Issuance of Common Equity		 0.00 0.00 93 61 65 87 - 0.00 25 273
Other Financing Activities, net		 0.01 0.00 0.03 2.02 3.07 3.36 0.00 134 231 7.54
Cash Interest Paid		 - - - - - - 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 - - - - - - 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Dianthus Therapeutics

This table details how cash moves in and out of Dianthus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 117 -25 197 -16 -280 -11 -13 3.12 43 -4.90 577
Net Cash From Operating Activities		 -9.99 -12 -15 -15 -21 -27 -28 -24 -31 -47 -29
Net Cash From Continuing Operating Activities		 -9.99 -12 -15 -15 -21 -27 -28 -24 -31 -47 -29
Net Income / (Loss) Continuing Operations		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -64 -41
Consolidated Net Income / (Loss)		 -15 -11 -14 -18 -25 -28 -30 -32 -37 -64 -41
Depreciation Expense		 0.02 0.02 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Amortization Expense		 -0.26 -0.44 -0.43 -0.33 -2.25 -2.69 -1.79 -1.03 -2.24 -0.79 -1.17
Non-Cash Adjustments To Reconcile Net Income		 1.08 1.06 1.78 2.71 3.08 5.37 6.12 6.49 5.57 4.92 11
Changes in Operating Assets and Liabilities, net		 3.94 -1.93 -2.56 0.68 3.06 -1.72 -2.47 2.25 2.86 13 2.22
Net Cash From Investing Activities		 -12 -8.24 -5.51 1.17 -259 -23 15 26 -201 37 -134
Net Cash From Continuing Investing Activities		 -12 -8.24 -5.51 1.17 -259 -23 15 26 -201 37 -134
Purchase of Property, Plant & Equipment		 -0.07 -0.01 -0.03 -0.02 -0.03 -0.03 -0.02 -0.05 -0.01 -0.14 -0.01
Purchase of Investments		 -27 -26 -20 -6.81 -278 -108 -67 -33 -280 -55 -239
Sale and/or Maturity of Investments		 16 18 15 8.00 19 85 82 60 79 92 105
Net Cash From Financing Activities		 138 -4.87 218 -2.20 0.30 40 0.16 0.57 275 4.88 739
Net Cash From Continuing Financing Activities		 138 -4.87 218 -2.20 0.30 40 0.16 0.57 275 4.88 739
Issuance of Debt		 - - - - - - 0.00 - - - 678
Issuance of Common Equity		 - - 0.00 -2.24 - - 0.13 - 272 0.00 59
Other Financing Activities, net		 138 -4.87 230 0.05 0.30 0.48 0.03 0.57 2.06 4.88 2.94

Annual Balance Sheets for Dianthus Therapeutics

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 54 157 162 162 190 83 179 374 531
Total Current Assets		 53 145 150 152 181 82 177 281 409
Cash & Equivalents		 51 58 65 58 132 15 132 23 51
Short-Term Investments		 0.00 84 81 91 45 60 41 252 353
Accounts Receivable		 - - - - - 4.70 0.29 0.81 0.05
Prepaid Expenses		 0.94 2.75 4.11 2.69 3.77 0.91 3.26 4.86 5.09
Plant, Property, & Equipment, net		 1.96 10 9.89 8.31 7.46 0.14 0.19 0.19 0.30
Total Noncurrent Assets		 0.00 1.78 1.78 1.78 1.78 0.94 1.77 93 121
Long-Term Investments		 - - - - - - 0.00 82 110
Other Noncurrent Operating Assets		 0.00 1.78 1.78 1.78 1.78 0.94 1.77 11 11
Total Liabilities & Shareholders' Equity		 54 157 162 162 190 83 179 374 531
Total Liabilities		 4.14 12 20 18 17 9.45 11 22 38
Total Current Liabilities		 4.14 10 14 11 11 8.23 9.63 18 31
Accounts Payable		 0.17 3.49 2.81 3.76 3.04 1.17 2.61 4.58 9.73
Accrued Expenses		 3.98 6.93 11 7.67 7.82 6.61 6.50 13 19
Current Deferred Revenue		 - - - - - 0.10 0.10 0.48 1.19
Other Current Liabilities		 - - - - 0.00 0.35 0.42 0.32 0.37
Total Noncurrent Liabilities		 0.00 1.25 6.21 6.28 6.40 1.23 0.90 3.08 6.79
Noncurrent Deferred Revenue		 - 1.25 6.21 6.28 6.40 0.79 0.74 1.91 5.77
Other Noncurrent Operating Liabilities		 0.00 - - - 0.00 0.44 0.17 1.17 1.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -42 146 141 144 173 -44 169 352 493
Total Preferred & Common Equity		 -42 146 141 144 173 -44 169 352 493
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -42 146 141 144 173 -44 169 352 493
Common Stock		 3.09 248 321 398 498 1.66 258 527 830
Retained Earnings		 -45 -103 -179 -254 -326 -46 -89 -174 -337
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 0.01 -0.02 -0.03 -0.16 0.05 0.11 0.49

Quarterly Balance Sheets for Dianthus Therapeutics

This table presents Dianthus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 83 79 192 382 369 354 349 326 577 1,247
Total Current Assets		 83 79 191 381 366 287 271 264 414 1,120
Cash & Equivalents		 49 63 157 330 314 34 10 13 56 628
Short-Term Investments		 30 15 33 47 47 247 253 244 347 484
Accounts Receivable		 - - 0.75 0.44 0.84 1.39 1.00 0.04 5.00 1.23
Prepaid Expenses		 2.91 1.05 0.83 3.01 3.31 3.68 6.77 6.18 6.21 7.42
Plant, Property, & Equipment, net		 0.00 0.00 0.20 0.20 0.19 0.19 0.19 0.21 0.19 0.27
Total Noncurrent Assets		 0.00 0.00 0.81 1.34 3.08 67 77 62 163 127
Long-Term Investments		 - - - - - 61 68 52 153 114
Other Noncurrent Operating Assets		 0.00 0.00 0.81 1.34 3.08 5.09 9.08 11 11 13
Total Liabilities & Shareholders' Equity		 83 79 192 382 369 354 349 326 577 1,247
Total Liabilities		 5.98 4.03 14 9.78 11 16 20 23 31 46
Total Current Liabilities		 5.98 4.03 13 8.96 10 16 17 20 24 38
Accounts Payable		 1.08 0.81 1.37 2.61 3.70 7.57 8.27 5.40 6.71 5.27
Accrued Expenses		 4.90 3.22 11 5.85 5.86 7.73 7.98 14 16 31
Current Deferred Revenue		 - - 0.10 0.10 0.10 0.10 0.48 0.48 0.95 1.49
Other Current Liabilities		 0.00 0.00 0.41 0.40 0.38 0.31 0.23 0.21 0.22 0.40
Total Noncurrent Liabilities		 0.00 0.00 1.00 0.82 0.71 0.64 3.02 2.90 7.14 7.29
Noncurrent Deferred Revenue		 - - 0.75 0.72 0.68 0.64 1.85 1.79 6.07 6.32
Other Noncurrent Operating Liabilities		 0.00 0.00 0.26 0.10 0.03 0.00 1.17 1.12 1.07 0.97
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 77 75 178 373 358 338 329 303 546 1,201
Total Preferred & Common Equity		 77 75 178 373 358 338 329 303 546 1,201
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 77 75 178 373 358 338 329 303 546 1,201
Common Stock		 509 509 257 476 479 483 532 539 819 1,579
Retained Earnings		 -431 -434 -79 -103 -121 -146 -204 -236 -272 -378
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.00 -0.00 -0.03 -0.04 0.68 0.27 0.10 0.16 -0.58

Annual Metrics And Ratios for Dianthus Therapeutics

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 33,151,539.00 38,989,517.00 48,304,981.00 58,777,271.00 - - - 42,876,015.00
DEI Adjusted Shares Outstanding		 0.00 0.00 33,151,539.00 38,989,517.00 48,304,981.00 58,777,271.00 - - - 42,876,015.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.74 -1.97 -1.55 -1.21 - - - -3.79
Growth Metrics		 - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -6.49 -25 -42 -58 -55 -52 -21 -34 -71 -125
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -19.97% -20.23% -25.24%
Earnings before Interest and Taxes (EBIT)		 -9.27 -36 -60 -83 -79 -75 -30 -48 -102 -179
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.26 -35 -59 -82 -77 -73 -30 -49 -108 -185
Valuation Ratios		 - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -24 -46 -50 -55 -53 -23 -31 -72 -108
Efficiency Ratios		 - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -1.25 3.08 -4.54 -4.93 -4.25 -1.83 -4.85 -4.49 -21
Increase / (Decrease) in Invested Capital		 0.00 -1.25 4.32 -7.61 -0.39 0.68 2.42 -3.01 0.36 -17
Book Value per Share		 $0.00 ($22.68) $4.39 $3.62 $2.98 $2.94 ($50.75) $11.40 $11.91 $11.51
Tangible Book Value per Share		 $0.00 ($22.68) $4.39 $3.62 $2.98 $2.94 ($50.75) $11.40 $11.91 $11.51
Total Capital		 0.00 50 146 141 144 173 74 169 352 493
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -52 -143 -146 -149 -177 -75 -174 -357 -514
Capital Expenditures (CapEx)		 0.14 2.20 7.66 3.06 0.40 1.26 0.14 0.11 0.11 0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.21 -7.67 -10 -8.74 -7.10 -1.68 -5.90 -13 -26
Debt-free Net Working Capital (DFNWC)		 0.00 48 135 136 140 170 74 168 262 379
Net Working Capital (NWC)		 0.00 48 135 136 140 170 74 168 262 379
Net Nonoperating Expense (NNE)		 2.94 10 16 19 20 19 7.68 9.83 14 38
Net Nonoperating Obligations (NNO)		 0.00 -52 -143 -146 -149 -177 -75 -174 -357 -514
Total Depreciation and Amortization (D&A)		 0.01 0.38 0.69 0.83 2.16 2.02 -0.46 -1.07 -5.61 -5.74
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($1.29) ($8.45) ($2.55) ($4.20)
Adjusted Weighted Average Basic Shares Outstanding		 149.41K 1.86M 33.47M 39.33M 48.56M 54.95M 59.37M 5.15M 33.31M 38.62M
Adjusted Diluted Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) ($1.29) ($1.29) ($8.45) ($2.55) ($4.20)
Adjusted Weighted Average Diluted Shares Outstanding		 149.41K 1.86M 33.47M 39.33M 48.56M 54.95M 59.37M 5.15M 33.31M 38.62M
Adjusted Basic & Diluted Earnings per Share		 ($65.15) ($19.12) ($3.13) ($2.07) ($1.71) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 149.41K 1.86M 18.39M 37.01M 43.92M 58.80M 60.64M 29.35M 32.13M 44.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.49 -25 -42 -58 -55 -52 -21 -34 -71 -125
Debt Service Ratios		 - - - - - - - - - -
Payout Ratios		 - - - - - - - - - -

Quarterly Metrics And Ratios for Dianthus Therapeutics

This table displays calculated financial ratios and metrics derived from Dianthus Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 32,125,179.00 32,159,982.00 32,188,345.00 42,876,015.00 44,471,094.00
DEI Adjusted Shares Outstanding		 - - - - - - 32,125,179.00 32,159,982.00 32,188,345.00 42,876,015.00 44,471,094.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.92 -0.98 -1.14 -1.50 -0.92
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -21.23% -91.29% 83.61% 92.26% 135.06% 190.15% 33.07% -100.00% -100.00% - -100.00%
EBITDA Growth		 -74.86% -166.78% -130.57% -89.32% -98.62% -161.25% -90.78% -59.39% -34.60% - -36.70%
EBIT Growth		 -92.56% -163.55% -133.53% -88.68% -87.58% -149.33% -85.32% -57.13% -37.24% - -40.52%
NOPAT Growth		 -90.93% -144.31% -132.25% -88.55% -89.73% -146.34% -85.93% -57.30% -34.74% - -40.26%
Net Income Growth		 -89.66% -154.09% -93.93% -58.05% -70.52% -169.24% -114.66% -79.64% -46.04% - -38.37%
EPS Growth		 57.53% 170.29% 93.33% 95.99% 80.42% -104.70% -51.85% -72.55% -31.08% - -3.66%
Operating Cash Flow Growth		 -161.02% -33.93% -45.28% -207.08% -112.84% -131.52% -84.93% -64.45% -43.67% - -4.44%
Free Cash Flow Firm Growth		 105.26% -133.55% -45.09% -78.23% -6,154.62% -274.84% -119.82% -30.42% 13.84% - 52.55%
Invested Capital Growth		 0.00% -164.34% -41.75% 16.73% 59.03% 7.34% 32.58% -141.66% -91.91% - -712.18%
Revenue Q/Q Growth		 -4.64% -50.54% 91.25% 113.16% 16.59% -38.95% -12.29% -100.00% 0.00% - -100.00%
EBITDA Q/Q Growth		 -34.16% 16.23% -36.86% -23.09% -40.74% -10.19% 0.06% -2.84% -18.85% - 32.20%
EBIT Q/Q Growth		 -33.51% 17.63% -38.16% -24.18% -32.73% -9.49% -2.69% -5.29% -15.93% - 33.10%
NOPAT Q/Q Growth		 -33.82% 17.79% -37.73% -24.43% -34.66% -6.74% -3.95% -5.27% -15.35% - 33.09%
Net Income Q/Q Growth		 -32.52% 28.45% -30.15% -28.07% -42.98% -12.97% -3.77% -7.18% -16.24% - 36.62%
EPS Q/Q Growth		 70.31% 527.51% -103.34% 5.56% -45.10% -2.70% -7.89% -7.32% -10.23% - 44.44%
Operating Cash Flow Q/Q Growth		 -111.20% -18.63% -26.04% 2.76% -46.39% -29.05% -0.68% 13.53% -27.89% - 38.58%
Free Cash Flow Firm Q/Q Growth		 105.08% -1,422.96% -85.13% -43.11% -72.74% 18.10% -8.56% 15.09% -14.11% - 63.62%
Invested Capital Q/Q Growth		 -284.38% 57.80% 10.29% 42.77% -89.11% 4.57% 34.73% -105.15% -50.17% - -13.24%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 -1,735.17% -2,938.95% -2,103.09% -1,214.49% -1,466.11% -2,646.23% -3,015.31% 0.00% 0.00% - 0.00%
Operating Margin		 -1,705.52% -2,835.01% -2,041.65% -1,191.84% -1,376.61% -2,406.94% -2,852.71% 0.00% 0.00% - 0.00%
EBIT Margin		 -1,708.87% -2,846.17% -2,056.06% -1,197.80% -1,363.67% -2,445.70% -2,863.46% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 -1,597.73% -2,311.38% -1,573.00% -945.09% -1,159.02% -2,144.80% -2,537.49% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.39% - 100.75%
Interest Burden Percent		 93.50% 81.21% 76.51% 78.90% 84.99% 87.70% 88.62% 90.20% 91.00% - 86.61%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -15.09% -35.92% -22.31% -26.19% -25.99% -32.60% -28.73% -34.71% -28.57% - -22.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 -135.19% -61.28% -28.46% -22.04% -26.77% -55.11% -51.11% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 -126.40% -49.76% -21.77% -17.39% -22.75% -48.33% -45.29% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -15.09% -18.44% -22.31% -26.19% -25.99% -32.60% -28.73% -34.71% -28.57% - -22.70%
Return on Equity Simple (ROE_SIMPLE)		 -7.55% 0.00% -13.47% -15.82% -19.86% 0.00% -30.65% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -9.07 -12 -16 -21 -22 -23 -24 -28 -49 -33
NOPAT Margin		 -1,193.86% -1,984.51% -1,429.15% -834.29% -963.63% -1,684.86% -1,996.90% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.93% -1.20% -0.55% -0.94% -1.59% -2.30% -1.77% -2.14% -1.91% - -1.06%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.37% - - - -6.34% -7.07% -8.07% -5.16% -9.87% -2.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 944.05% 1,013.57% 645.31% 321.90% 300.55% 515.01% 630.87% 0.00% 0.00% - 0.00%
R&D to Revenue		 861.47% 1,921.44% 1,496.34% 969.94% 1,176.06% 1,991.93% 2,321.84% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 1,805.52% 2,935.01% 2,141.65% 1,291.84% 1,476.61% 2,506.94% 2,952.71% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -13 -18 -22 -30 -32 -33 -35 -41 -70 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -13 -18 -23 -32 -35 -35 -36 -43 -71 -48
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.65 0.91 2.36 2.12 2.38 1.83 1.77 1.98 2.32 - 3.11
Price to Tangible Book Value (P/TBV)		 4.65 0.91 2.36 2.12 2.38 1.83 1.77 1.98 2.32 - 3.11
Price to Revenue (P/Rev)		 108.93 54.53 273.08 184.45 149.78 103.48 89.32 128.54 508.88 - 4,274.93
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 83.99 0.00 156.13 96.86 85.93 46.23 38.51 62.23 285.71 - 2,871.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 549.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.06 -1.03 -1.02 -1.01 -1.03 -1.02 -1.01 -1.01 -1.02 - -1.02
Leverage Ratio		 1.08 1.08 1.04 1.03 1.06 1.06 1.04 1.05 1.05 - 1.04
Compound Leverage Factor		 1.01 0.88 0.79 0.82 0.90 0.93 0.92 0.95 0.96 - 0.90
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 35.64 8.98 54.68 42.94 29.58 17.90 17.26 15.18 24.44 - 49.63
Noncontrolling Interest Sharing Ratio		 0.00% 48.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.64 18.43 42.52 36.46 18.30 15.22 15.99 13.12 17.35 - 29.25
Quick Ratio		 14.57 18.07 42.13 36.05 17.98 14.96 15.59 12.81 17.09 - 29.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.46 -6.06 -11 -16 -28 -23 -25 -21 -24 -32 -12
Operating Cash Flow to CapEx		 -15,372.31% -118,540.00% -46,690.63% -85,458.82% -85,068.00% -88,529.03% -115,125.00% -51,939.13% -611,100.00% - -288,560.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.08 0.02 0.01 0.02 0.02 0.02 0.02 0.01 0.01 - 0.00
Accounts Receivable Turnover		 0.00 1.13 0.00 0.00 5.01 11.33 9.09 10.61 0.78 - 0.78
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 17.28 0.00 0.00 27.95 32.90 33.80 23.54 13.31 - 3.75
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 322.51 0.00 0.00 72.82 32.23 40.14 34.42 468.53 - 466.18
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 322.51 0.00 0.00 72.82 32.23 40.14 34.42 468.53 - 466.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -11 -4.85 -4.35 -2.49 -4.71 -4.49 -2.93 -6.02 -9.03 -21 -24
Invested Capital Turnover		 -1.33 -0.85 -0.87 -1.50 -0.66 -1.34 -1.79 -1.10 -0.36 - -0.07
Increase / (Decrease) in Invested Capital		 -11 -3.01 -1.28 0.50 6.78 0.36 1.42 -3.53 -4.33 -17 -21
Enterprise Value (EV)		 639 -20 503 399 461 288 251 290 711 - 2,507
Market Capitalization		 829 154 880 760 804 645 583 599 1,267 - 3,732
Book Value per Share		 $2.94 $11.40 $12.70 $12.21 $11.51 $11.91 $10.23 $9.42 $16.98 $11.51 $27.01
Tangible Book Value per Share		 $2.94 $11.40 $12.70 $12.21 $11.51 $11.91 $10.23 $9.42 $16.98 $11.51 $27.01
Total Capital		 178 169 373 358 338 352 329 303 546 493 1,201
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -190 -174 -377 -361 -343 -357 -332 -309 -555 -514 -1,225
Capital Expenditures (CapEx)		 0.07 0.01 0.03 0.02 0.03 0.03 0.02 0.05 0.01 0.14 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -5.90 -5.07 -5.05 -9.34 -13 -9.18 -14 -13 -26 -30
Debt-free Net Working Capital (DFNWC)		 178 168 372 356 272 262 254 244 390 379 1,082
Net Working Capital (NWC)		 178 168 372 356 272 262 254 244 390 379 1,082
Net Nonoperating Expense (NNE)		 3.73 1.49 1.26 2.06 4.24 6.10 6.29 7.18 8.56 16 8.26
Net Nonoperating Obligations (NNO)		 -190 -174 -377 -361 -343 -357 -332 -309 -555 -514 -1,225
Total Depreciation and Amortization (D&A)		 -0.24 -0.42 -0.41 -0.31 -2.23 -2.66 -1.77 -1.00 -2.21 -0.76 -1.14
Debt-free, Cash-free Net Working Capital to Revenue		 -151.00% -208.70% -157.23% -122.61% -174.13% -205.12% -140.77% -297.73% -507.96% - -3,394.16%
Debt-free Net Working Capital to Revenue		 2,343.02% 5,938.43% 11,537.44% 8,636.67% 5,064.83% 4,209.33% 3,894.02% 5,224.46% 15,667.74% - 123,897.82%
Net Working Capital to Revenue		 2,343.02% 5,938.43% 11,537.44% 8,636.67% 5,064.83% 4,209.33% 3,894.02% 5,224.46% 15,667.74% - 123,897.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.78) $16.16 ($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85)
Adjusted Weighted Average Basic Shares Outstanding		 3.91M 5.15M 25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M
Adjusted Diluted Earnings per Share		 ($3.78) $16.16 ($0.54) ($0.51) ($0.74) ($0.76) ($0.82) ($0.88) ($0.97) ($1.53) ($0.85)
Adjusted Weighted Average Diluted Shares Outstanding		 3.91M 5.15M 25.67M 34.23M 34.24M 33.31M 35.79M 35.82M 37.79M 38.62M 48.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 14.82M 29.35M 29.35M 29.35M 29.60M 32.13M 32.16M 32.19M 42.88M 44.47M 54.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -9.07 -12 -16 -21 -22 -23 -24 -28 -49 -33
Normalized NOPAT Margin		 -1,193.86% -1,984.51% -1,429.15% -834.29% -963.63% -1,684.86% -1,996.90% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 -1,597.73% -2,311.38% -1,573.00% -945.09% -1,159.02% -2,144.80% -2,537.49% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Dianthus Therapeutics (NASDAQ: DNTH) remains an early-stage biotech story with no product revenue yet, but its latest quarterly filings show a very strong liquidity position after a large financing raise. The tradeoff is continued heavy operating losses and cash burn as the company funds research and development.

  • Cash position surged in Q1 2026. DNTH ended the quarter with about $1.11 billion in total current assets, including $627.7 million in cash and equivalents and $483.6 million in short-term investments.
  • Balance sheet strength improved dramatically year over year. Total assets rose to $1.25 billion in Q1 2026 from $577.4 million in Q3 2025, driven mainly by financing activity.
  • Liquidity runway appears extended. With $1.22 billion in cash, equivalents, and investments, the company should have substantial flexibility to fund clinical development.
  • Financing gave DNTH a major capital cushion. Q1 2026 included $677.6 million of debt issuance and $58.9 million of common equity issuance, boosting cash significantly.
  • Interest income is helping offset some losses. The company generated $6.3 million of interest and investment income in Q1 2026, up from $5.3 million in Q4 2025.
  • Operating cash burn narrowed sequentially. Cash used in operations improved to -$28.9 million in Q1 2026 from -$46.98 million in Q4 2025.
  • Revenue remains minimal and inconsistent. Q1 2026 reported $0 revenue, while prior quarters showed only small collaboration-related revenue, which is not enough to cover expenses.
  • R&D spending remains the core use of capital. Research and development expense was still high at $34.5 million in Q1 2026, compared with $59.9 million in Q4 2025 and $32.5 million in Q3 2025.
  • Losses remain substantial. DNTH posted a net loss of $40.8 million in Q1 2026, after a $64.4 million loss in Q4 2025 and $36.8 million in Q3 2025.
  • Operations are still burning cash. Even with the huge balance sheet, Q1 2026 operating activities consumed $28.9 million, underscoring that the business is not self-funding.

Bottom line: DNTH’s latest quarter looks financially stronger from a liquidity standpoint, thanks to a very large financing event. That said, investors should still expect continued losses and meaningful R&D spending until the company can advance its pipeline closer to commercialization or secure additional partnership revenue.

07/15/26 07:56 AM ETAI Generated. May Contain Errors.

Dianthus Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Dianthus Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Dianthus Therapeutics' net income appears to be on an upward trend, with a most recent value of -$162.34 million in 2025, rising from -$9.43 million in 2016. The previous period was -$84.97 million in 2024. See where experts think Dianthus Therapeutics is headed by visiting Dianthus Therapeutics' forecast page.

Dianthus Therapeutics' total operating income in 2025 was -$177.93 million, based on the following breakdown:
  • Total Gross Profit: $2.04 million
  • Total Operating Expenses: $179.97 million

Over the last 9 years, Dianthus Therapeutics' total revenue changed from $0.00 in 2016 to $2.04 million in 2025, a change of 203,600,000.0%.

Dianthus Therapeutics' total liabilities were at $37.52 million at the end of 2025, a 74.3% increase from 2024, and a 805.9% increase since 2017.

In the past 8 years, Dianthus Therapeutics' cash and equivalents has ranged from $15.37 million in 2022 to $132.33 million in 2023, and is currently $51.09 million as of their latest financial filing in 2025.

Over the last 9 years, Dianthus Therapeutics' book value per share changed from 0.00 in 2016 to 11.51 in 2025, a change of 1,150.8%.


Related Companies

Financial statements for NASDAQ:DNTH last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel